Nykode Therapeutics AS
5VB
Company Profile
Business description
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
Contact
Gaustadalleen 21
Oslo Research Park
Oslo0349
NORT: +47 22958193
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
57
Stocks News & Analysis
stocks
Chart of the Week: BHP’s valuation hits historic levels
BHP and peers are trading as if the copper boom is here to stay.
stocks
3 cheap wide moat growth stocks
4 and 5 star companies that can protect and grow their earnings.
stocks
ASX biotech expands diagnostics portfolio after FDA approval
FDA nod adds another growth driver for ASX share.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,910.90 | 36.40 | 0.41% |
| CAC 40 | 8,186.93 | 0.00 | 0.00% |
| DAX 40 | 25,716.71 | 178.96 | 0.70% |
| Dow JONES (US) | 51,802.29 | 340.39 | 0.66% |
| FTSE 100 | 10,816.14 | 127.67 | 1.19% |
| HKSE | 24,604.29 | 109.49 | -0.44% |
| NASDAQ | 26,408.40 | 429.98 | 1.66% |
| Nikkei 225 | 64,136.25 | 213.25 | 0.33% |
| NZX 50 Index | 13,756.59 | 133.87 | 0.98% |
| S&P 500 | 7,637.93 | 86.12 | 1.14% |
| S&P/ASX 200 | 8,732.40 | 35.90 | 0.41% |
| SSE Composite Index | 3,875.60 | 16.00 | -0.41% |